Abstract
AbstractRespiratory syncytial virus (RSV) is a leading cause of severe respiratory disease for which no licensed vaccine is available. We have previously shown that a prefusion (preF) conformation-stabilized RSV F protein antigen and an adenoviral vector encoding RSV preF protein (Ad26.RSV.preF) are immunogenic and protective in animals when administered as single components. Here, we evaluated a combination of the 2 components, administered as a single injection. Strong induction of both humoral and cellular responses was shown in RSV-naïve and pre-exposed mice and pre-exposed African green monkeys (AGMs). Both components of the combination vaccine contributed to humoral immune responses, while the Ad26.RSV.preF component was the main contributor to cellular immune responses in both mice and AGMs. Immunization with the combination elicited superior protection against RSV A2 challenge in cotton rats. These results demonstrate the advantage of a combination vaccine and support further clinical development.
Funder
Janssen Pharmaceuticals
U.S. Department of Health & Human Services | National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Infectious Diseases,Pharmacology,Immunology
Reference54 articles.
1. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749–1759 (2005).
2. Stockman, L. J., Curns, A. T., Anderson, L. J. & Fischer-Langley, G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr. Infect. Dis. J. 31, 5–9 (2012).
3. Falsey, A. R. & Walsh, E. E. Respiratory syncytial virus infection in adults. Clin. Microbiol. Rev. 13, 371–384 (2000).
4. National Institutes of Health & National Institute of Allergy and Infectious Diseases. Respiratory syncytial virus (RSV). https://www.niaid.nih.gov/diseases-conditions/respiratory-syncytial-virus-rsv (2008). Accessed 28 March 2022.
5. Falsey, A. R. et al. Risk factors and medical resource utilization of respiratory syncytial virus, human metapneumovirus and influenza related hospitalizations in adults—a global study during the 2017–2019 epidemic seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] study). Open Forum Infect. Dis. 8, ofab491 (2021).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Mucosal delivery of a prefusogenic-F, glycoprotein, and matrix proteins-based virus-like particle respiratory syncytial virus vaccine induces protective immunity as evidenced by challenge studies in mice;Virology;2024-10
2. A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older;Influenza and Other Respiratory Viruses;2024-06
3. Immunogenicity and safety of Ad26.RSV.preF/RSV preF protein vaccine at predicted intermediate- and end-of-shelf-life as an evaluation of potency throughout shelf life;Human Vaccines & Immunotherapeutics;2024-05-23
4. Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF–Based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study;The Journal of Infectious Diseases;2023-07-11